Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566262 · ClinicalTrials.gov registry record · Phase 4
Bodewell Products for the Treatment of Atopic Dermatitis
A Phase 4 study of Atopic Dermatitis, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05566262 is a Phase 4 study of Atopic Dermatitis that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 15 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05566262, a Phase 4 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
Conditions Studied
Interventions
- DRUG Bodewell Calming Cream
Study Locations (1)
Alabama
- The University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2028-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05566262
The ClinicalTrials.gov registry entry for NCT05566262 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (98% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Bodewell Calming Cream is the first listed.
NCT05566262 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05566262 about?
NCT05566262 is a clinical study titled "Bodewell Products for the Treatment of Atopic Dermatitis". This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
What is the current status of trial NCT05566262?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2023-11-01. Estimated completion is 2028-02.
What conditions does trial NCT05566262 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05566262?
The interventions under investigation include: Bodewell Calming Cream (DRUG).
Who is sponsoring clinical trial NCT05566262?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05566262 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.